Navigation Links
Alzheimer's disease in mice alleviated promising therapeutic approach for humans
Date:11/25/2012

Alzheimer's disease is one of the most common causes of dementia. In Germany and Switzerland alone, around 1.5 million people are affected, and forecasts predict a doubling of the number of patients worldwide within the next 20 years. The accumulation of particular abnormal proteins, including amyloid- (Aβ) among others, in patients' brains plays a central role in this disease. Prof. Frank Heppner from the Department of Neuropathology at Charit and his colleague Prof. Burkhard Becher from the Institute for Experimental Immunology at the University of Zurich were able to show that turning off particular cytokines (immune system signal transmitters) reduced the Alzheimer's typical amyloid- deposits in mice with the disease. As a result, the strongest effects were demonstrated after reducing amyloid- by approximately 65 percent, when the immune molecule p40 was affected, which is a component of the cytokines interleukin (IL)-12 and -23.

Relevant for human therapy

Follow-up experiments also relevant for humans showed that substantial improvements in behavioral testing resulted when mice were given the antibody blocking the immune molecule p40. This effect was also achieved when the mice were already showing symptoms of the disease. Based on the current study by Prof. Heppner's and Prof. Becher's team, the level of p40 molecules is higher in Alzheimer's patients' brain fluid, which is in agreement with a recently published study by American colleagues demonstrating increased p40 levels in blood plasma of subjects with Alzheimer's disease, thus showing obvious relevance for human therapy.

The significance of the immune system in Alzheimer's research is the focus of current efforts. Prof. Heppner and Prof. Becher suspect that cytokines IL-12 and IL-23 themselves are not causative in the pathology, and that the mechanism of the immune molecule p40 in Alzheimer's requires additional clarification. However, they are convinced that the results of their six-years of research work justify the step toward clinical studies in humans, for which they plan to collaborate with a suitable industrial partner.

IIn the context of other illnesses, such as psoriasis, a medication that suppresses p40 in humans has already been applied. "Based on the safety data in patients," comment Profs. Heppner and Becher, "clinical studies could now be implemented without delay. Now, the goal is to bring the new therapeutic approach to Alzheimer patients quickly."


'/>"/>
Contact: Prof. Burkhard Becher
becher@immunology.uzh.ch
41-446-353-703
University of Zurich
Source:Eurekalert  

Related biology news :

1. Short DNA strands in the genome may be key to understanding human cognition and diseases
2. Discovery of molecular pathway of Alzheimers disease reveals new drug targets
3. Scripps Research Institute team identifies a potential cause of Parkinsons disease
4. Yeast protein breaks up amyloid fibrils and disease protein clumps differently
5. Scientists question the designation of some emerging diseases
6. Call for global monitoring of infectious diseases in dogs and cats
7. Cells from skin create model of blinding eye disease
8. New drug target found for cystic fibrosis lung disease
9. Researchers test solution to fungal disease of ash trees
10. Daily multivitamin use does not reduce cardiovascular disease risk in men
11. Berkeley Lab scientists help develop promising therapy for Huntingtons disease
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Alzheimer's disease in mice alleviated promising therapeutic approach for humans
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market by Solution ... Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast to 2022", ... 14.30 Billion in 2017 to USD 31.75 Billion by 2022, at a ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... 11, 2017 No two people are ... the New York University Tandon School of Engineering ... found that partial similarities between prints are common ... mobile phones and other electronic devices can be ... vulnerability lies in the fact that fingerprint-based authentication ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute for ... Cell Explorer: a one-of-a-kind portal and dynamic digital window ... imaging data, the first application of deep learning to ... stem cell lines and a growing suite of powerful ... for these and future publicly available resources created and ...
Breaking Biology News(10 mins):
(Date:5/18/2017)... Malden, Mass. (PRWEB) , ... May 18, 2017 ... ... completed the procedure on April 28, 2017 at the Prince Of Wales Private ... degenerative cervical disc at level C6-C7. The patient failed conservative treatments prior to ...
(Date:5/18/2017)... ... May 16, 2017 , ... Clinical Supplies Management (“CSM”), a Great ... company continues to grow. CSM has doubled in size over the past six ... aggressive growth strategy. , Roger Gasper joins CSM as Chief Financial Officer. Roger ...
(Date:5/18/2017)... ... May 17, 2017 , ... ... enhances its scientific power by providing investigators access to a high-profile scientific ... join the scientific advisory board. “We are committed to offering superior services ...
(Date:5/18/2017)... SANTA BARBARA, CALIFORNIA (PRWEB) , ... May 17, ... ... risk management, technological innovation and business process optimization firm for the life sciences ... the Chairman of the UDIs and Traceability for Medical Devices conference in Brussels, ...
Breaking Biology Technology: